Plasminogen Market

Key data points: Market size in 2027 = $270.2 million and 2035 = $492.7 million, growth forecast = 39.5% annually for the next 8 years. Scroll below to get more insights. This market report covers trends, opportunities and forecasts in plasminogen market to 2035 by type (intravenous injection and eye drops), application (ligneous conjunctivitis, diabetic foot, wound healing, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World) Plasminogen Market The future of the global plasminogen market looks promising with opportunities in the ligneous conjunctivitis, diabetic foot, and wound healing markets. The global plasminogen market is expected to reach an estimated $492.7 million by 2035 from $270.2 million in 2027 with a CAGR of 39.5% from 2027 to 2035. The major drivers for this market are the increasing demand for plasminogen therapies, the rising prevalence of thrombotic disorders, and the growing investment in biotechnology research. • Lucintel forecasts that, within the type category, intravenous injection is expected to witness higher growth over the forecast period due to iv injection provides the fastest route of administration. • Within the application category, ligneous conjunctivitis is expected to witness the highest growth over the forecast period due to plasminogen is the only treatment available for ligneous conjunctivitis. • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to increased diagnosis and social factors will lead to greater demand for población treatment. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below. Emerging Trends in Plasminogen Market Between 2025 and 2027, the plasminogen market is expected to shift away from the current replacement therapy model and toward other markets, such as diagnostic testing. Additionally, the manufacture and distribution of plasminogen-based biologics is expected to increase. Regulatory agencies, the capacity of hospitals to perform diagnostic testing, and the level of investment by biopharmaceutical companies will influence the market. Lucintel has taken a similar market view. For plasminogen-based biologics, the relevance of clinical data and the ability of the manufacturers to ensure the reliable supply of their biologics is expected to play a greater role as compared to the size of the facilities in which the biologics are manufactured. • Earlier Diagnosis: From 2025 to 2027, it is anticipated that specialized testing centers will become available to diagnose congenital deficiencies of plasminogen. With a prevalence of 1.6 cases per million, the demand for long-term treatment is expected to increase. Additionally, the identification of patients at risk is expected to help prevent further damage to body tissues. • Specialty Biologics: During the same time frame, it is anticipated that little change will occur with respect to the only FDA-approved plasminogen replacement, Ryplazim. However, it is expected that the sponsoring company will make efforts to improve the stability and usability of the product. • Recombinant Plasminogen: Several companies are in the process of developing recombinant forms of plasminogen to reduce reliance on blood donations. While recombinant plasminogen may not be available on a commercial basis until after 2027, the technologies developed may improve the supply and reduce the reliance on a few companies. • Access-based Commercialization: Payers and accounts are requesting data that demonstrate how a therapy reduces the need for particular procedures or preserves sight. In the future, real world data will be used to answer these questions. Starting in 2025, payers will evaluate the evidence and adjust reimbursement. The goal will be to optimize spend to increase the number of treated patients. • Specialist Care Networks: There will be greater emphasis on coordinating specialty care. Beginning in 2025, management of high risk patients will be facilitated via improved teleconsultation and referral pathways. This will positively impact access to specialized care and services for patients living in remote areas. Greater diagnostic and therapeutic standardization will facilitate safe service delivery in previously unserved areas. In the next five years, a market will exist for plasminogen based on the ability to identify previously undiagnosed patients and demonstrate the therapy improves patients’ quality of life. Access to diagnostics and therapeutics will improve with greater education and collaboration between specialty pharma, biotech and diagnostics manufacturers. Stability and reliability of supply will be the most important factor differentiating suppliers. Recent Developments in the Plasminogen Market Rates of change in the plasminogen market are expected to be relatively slow from 2025 to 2027. Advances in plasminogen-related diagnostics and rare-disease plasma replacement therapies are expected to largely drive market activity during this period. Lucintel believes that, during this time frame, market development will be more limited by the availability of reliable, satisfactory, and compliant manufacturing sources than by the prevailing level of demand for broad-spectrum biologics. • Regulatory Consolidation: In 2021, the FDA granted marketing authorization to Bioverativ’s Ryplazim, thus becoming the only approved treatment for hereditary plasminogen deficiency. Between 2025 and 2027, sponsors will focus on post-market requirements and other evidence, thereby creating little to no market opportunities for first-in class plasminogen products. First-in-class products may, however, improve the confidence of treating physicians. • Plasma Supply: In addition to having a large, diversified customer base and an annual revenue exceeding one billion Euros, Kedrion also has a large and robust plasma-derivative manufacturing infrastructure. During the same time frame (2025-2027), other biopharmaceutical companies may also invest in large-scale plasma collection and fractionation to supply the growing demand for plasminogen products. • Diagnostics: In 2025, plasminogen activity and antigen testing were not widely available. Improved case identification may lead to earlier recognition of plasminogen deficiency. Case identification and diagnosis are anticipated to improve in the next five years. • Wound Healing: Increased interest is directed to the role of plasminogen in healing and fibrinolysis. Clinical data expected by 2025 will support greater than 100 patients with congenital deficiencies. While these data may provide the foundation to expand the product label, clinical studies in larger patient populations will be needed prior to broad adoption. • Partnerships: Manufacturing and commercialization of treatments for rare diseases have shifted to sponsorship of specialty treatment and distributorships to specialized treatment centers rather than promotion through the traditional primary care route. 2025 brought no changes to the weight-based (6.6 mg/kg) dosing of Ryplazim, and continued the requirement for specialized staff and facilities for administration. Future alliances and partnerships may broaden the geographic availability of treatment and decrease time to treatment in areas with restrictive reimbursement. Establishing a visible market presence, like Kedrion for plasminogen, and other pipeline projects, provide the foundation for plasminogen to move beyond current market replacements. Manufacturing and clinical demands of plasminogen will mainly dictate the market by 2030. Strategic Growth Opportunities in the Plasminogen Market Maintain structure and content (including specific bullet points, spacing, headings, etc.) as exactly as possible. Do not revise or change companies mentioned in content. Use correct spelling for Lucintel and all other companies. Plasminogen market is poised for transformation beyond traditional indications and is gaining traction in the field of rare- diseases. Lucintel forecasts positive market outlook during the forecast period 2024-2026. Plasminogen has various potential indications and commercial opportunities that will be realized with adoption of specialized centers and strategic investments. • Plasminogen Replacement Therapy for Ligneous Conjunctivitis: A randomized trial was initiated in May 2025 with goal to enroll 20 subjects to investigate the safety and efficacy of plasminogen for ligneous conjunctivitis. Upon completion of the trial, plasminogen may gain indication for other ophthalmic conditions beyond replacement therapy. • Cases of Severe Type 1 Plasminogen Deficiency in Pediatrics: If cases of severe type 1 plasminogen deficiency in pediatrics are identified, it may reduce the prevalence of irreversible tissue damage. A 2026 prospective registry aims to recruit 30 pediatric cases of severe type 1 plasminogen deficiency. • Recombinant Plasminogen: A 2025 clinical program aims to determine the safety and efficacy of a recombinant plasminogen product in adult subjects with bleeding episodes associated with plasminogen deficiency. The sponsor expects to launch the product if they achieve equivalent product potency to currently available plasma-derived plasminogen. • Geographic Expansion: The main markets remain specialty markets, and there is a lot of potential in Europe, the Middle East and the Asia-Pacific region. By March 2025, a global distributor of rare disease drugs operated in over 50 countries. The next couple of years are expected to bring more regulatory changes and the formation of more partnerships which will facilitate the expansion of rare disease drug access, as well as the establishment of named-patient pathways. • Diagnostic-related Services: There are opportunities to provide related services such as testing and/or patient monitoring in connection with the patient's treatment. In October 2025, a laboratory network announced that it expected to be able to perform rare coagulation tests within the next 14 days. Other laboratory tests related to rare diseases may also be able to provide similar results. Laboratories may be able to set up similar arrangements with product manufacturers to perform testing and/or case finding. There are a number of ways to sustain and enhance current revenue streams such as optimizing supply chain operations and adjusting pricing. However, in the long-term, there will be greater value in investing in funding research on the use of certain products for various rare conditions and aiding the development of reimbursement justifications for the use of such products. Plasminogen Market Drivers and Challenges Plasminogen is useful for treating some rare diseases and inflammatory conditions. With greater clinically recognized usage, the market is expected to grow. The ability of the market to grow is limited to the number of patients and the costs of production. From Lucintel viewpoint, the main barriers to commercialization are the availability of evidence, reimbursement, and reliability of the supply. Other barriers are regulatory approval and the balance of innovative therapies and affordability of the healthcare system. It is expected that in the next five years, the market will be combined by the efforts of the pharmaceutical companies to cover and reach the maximum number of patients that need their products. The factors responsible for driving this market include : • Increasing Need for Rare Disease Treatments: Better identification of patients with plasminogen deficiency and associated mucosal, ocular and respiratory conditions promoted the usage of targeted plasminogen replacement therapies. As of September 2025, plasminogen replacement therapy has been published for use in patients with severely deficient plasminogen levels. The number of patients who are potentially benefitted from the therapy is not known, but in the next three to five years, with the implementation of rare disease programs by various countries, better awareness among the medical fraternity and improvement in diagnosis, the number of patients identified will increase. • Improvement in Biologics Manufacturing: There have been numerous improvements in manufacturing of plasminogen and other biologics. As of March 2026, several biologics companies adopted new methods for the manufacturing of biologics. These new methods, along with others, are expected to improve the consistency of plasminogen and other biologics in next three to five years. Further, improvements in manufacturing may allow companies to produce biologics for very small, rare patient populations. • Diagnostics: Plasminogen deficiencies are still commonly mistaken for other medical conditions. However, innovations in laboratory tests are improving the differential diagnosis of plasminogen deficiencies. In 2025, standardized plasminogen tests became more common in rare disease centers. Additionally, the use of combination plasminogen tests along with genetic analyses became more standard. Looking forward, it is expected that in the next 3-5 years, additional specialized tests and laboratories will become available, further improving diagnosis and timely treatment of plasminogen deficiencies. Improved diagnosis of rare diseases can alleviate the medical and emotional burden on patients. Improving access to diagnostic testing for rare diseases will facilitate the creation of disease-specific resources, especially for conditions that lack extensive health care and research infrastructure. • Pharmaceuticals: In 2025, numerous laws and policies across the globe improved the pharmaceutical industry’s view of rare disease drugs and plasminogen replacement therapies. Additionally, in 2025, regulatory agencies stated their commitment to small patient populations and encouraged the development of rare disease drugs. The commitment of regulatory agencies is expected to improve the rare disease drug development process and create a positive environment for sponsors to address unmet needs. While manufacturing and clinical evidence will remain the responsibility of pharmaceutical companies, the committee expected the regulatory agencies would support and speed the rare disease drug development process. • New Product Development and Widened Clinical Application: Ongoing research on optimal dosing and alternate modes of delivery may allow the use of this product beyond the current indications. There is potential to utilize this product for the treatment of various inflammatory conditions and for the promotion of tissue healing. As of February 2026, studies focused on description of treatment in free-living-conditions and documentation of long-term outcomes. More innovations within the product may improve convenience, product satisfaction, and benefit to the patient. The development of new indications is highly dependent on the availability of supporting data. The challenges facing this market include: • High Treatment Price and Lack of Reimbursement: Current methods for the treatment of these ultra-rare diseases involve the production of individualized and highly controlled biologics, resulting in very high costs. As of July 2025, the main focus of payers was on the benefits and durability of the treatment, as well as the expected impact on the payers’ budget. It is expected that during the next 3 to 5 years, health care systems will perform a more rigorous economic assessment prior to reimbursement, resulting in limited access to the treatment. If this occurs, particularly in low income countries, the demand for the treatment will not be met. • Patient Population and Diagnostics: Plasminogen deficiency is rare and symptoms are similar to other more prevalent conditions. Therefore, many cases remain undiagnosed or misdiagnosed. As of November 2025, specialist networks reported the need for international collaboration and centralized testing to standardize diagnosis. Estimates suggest that in the next few years, the obstacles posed by the small and distant population of individuals with this condition will make it difficult to determine the demand and to transport the treatment to where it is needed. Undiagnosed cases can increase the disease’s prevalence, and the difficulty in measuring the disease’s true extent makes it challenging to evaluate the impact of treatment. Many affected individuals are in developing countries. There is little information about the prevalence and distribution of the disease. To reduce the prevalence of this condition, the development of national and international referral and consultation systems, as well as specialized training, is essential. • Supply and Demand Challenges: The transport and storage of biopharmaceutical products require special facilities, and an adequate supply of raw materials, posing a challenge to manufacturers. In 2026, companies anticipated disruptions in raw material supply. Dual sourcing of raw materials is common. For the next 5 to 7 years, expectations of batch failures and other supply issues will likely result in significant disruptions in the market and further erode physician trust. Smaller markets, in particular, may create situations of high market concentration, since the presence of only a single supplier in the market would be economically unviable. As a result, reliability of supply may require the implementation of a combination of strategies including, supply chain management, logistics and inventory policies. The market for plasminogen is likely to grow with improvement in diagnosis and policies that increase awareness and support for rare diseases. Additionally, the reliability of the biologics industry may facilitate the supply of other clot buster drugs. Newer and innovative drugs may facilitate wider use of existing drugs. Improvements in diagnostics may allow identification of previously undiagnosed cases. There will likely be continued increased interest in the development of plasminogen based drugs. The main challenges to the market development of plasminogen based drugs will likely be the price, especially public insurance reimbursement. Other challenges may include the unmet need, insufficient clinical data, and supply. Most likely, the market will be driven by the collaborative efforts of pharmaceutical companies, academia and the healthcare industry to provide more affordable and reliable drugs. List of Plasminogen Market Companies Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies plasminogen market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the plasminogen market companies profiled in this report include- • Kedrion S.p.A. • Grifols, S.A. • CSL Behring • Takeda Pharmaceutical Company Limited • Octapharma AG Plasminogen Market by Segment The study includes a forecast for the global plasminogen market by type, application, and region. Plasminogen Market by Type [Value ($M) from 2019 to 2035]: • Intravenous Injection • Eye Drops Plasminogen Market by Application [Value ($M) from 2019 to 2035]: • Ligneous Conjunctivitis • Diabetic Foot • Wound Healing • Others Plasminogen Market by Region [Value ($M) from 2019 to 2035]: • North America • Europe • Asia Pacific • The Rest of the World Country Wise Outlook for the Plasminogen Market Access to specialized manufacturing, and rare disease designations influence the plasminogen market. Around 2025-2027, companies will be focused on securing reliable sources of plasma in addition to purification processes and reimbursement. Lucintel has sweat the major constraints of market potential at this time. • Unites States: In 2021, the FDA approved the first Plasminogen Replacement Therapy (Ryplazim). With its designation as an Orphan Drug, the FDA will likely give Ryplazim, and similar products in the future, a pathway for expansion of its labeling. Other products in this category will likely face similar trajectories. • China: In September 2023, the Chinese National Medical Products Administration (NMPA) released an updated list of rare diseases (207), and will continue to provide designation pathways. Like Germany, increases in biopharmaceutical manufacturing will occur, and with the guidance of China's NMPA, technology and manufacturing partnerships will form for plasminogen. • Germany: The announcement by Biotest in September 2024 to significantly increase its plasma processing capacity in Europe, will fortify the regional supply of specialized plasma products. • India: The Indian Department of Pharmaceuticals launched the National Biopharma Mission in July 2017, with a target of 15000 million INR (approximately 2 billion USD) to foster research and develop manufacturing facilities for biologics. Investments in the biologics space will help further build the country’s capacity in developing plasma protein therapies. • Japan: In April 2025, Japan’s Ministry of Health, Labor and Welfare decided to include 341 diseases in its “Designated Intractable Diseases” list. Plasma-derived therapies are intended for rare diseases, and if Japan continues to add these therapies to its recognized list, plasminogen therapy is expected to be covered in the list and reimbursed in the next 3-5 years. Features of the Global Plasminogen Market Market Size Estimates: plasminogen market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions. Segmentation Analysis: plasminogen market size by type, application, and region in terms of value ($B). Regional Analysis: plasminogen market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the plasminogen market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the plasminogen market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model. If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more. This report answers following 11 key questions: Q.1. What are some of the most promising, high-growth opportunities for the plasminogen market by type (intravenous injection and eye drops), application (ligneous conjunctivitis, diabetic foot, wound healing, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)? Q.2. Which segments will grow at a faster pace and why? Q.3. Which region will grow at a faster pace and why? Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market? Q.5. What are the business risks and competitive threats in this market? Q.6. What are the emerging trends in this market and the reasons behind them? Q.7. What are some of the changing demands of customers in the market? Q.8. What are the new developments in the market? Which companies are leading these developments? Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth? Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution? Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?